Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: lapatinib ditosylate|BIOLOGICAL: trastuzumab
Sponsor: Washington University School of Medicine